Abstract:Chronic hepatitis C virus infection represents a serious global public health problem, typically resulting in fibrosis, cirrhosis, and ultimately hepatocellular carcinoma. Based on our previous discovery of lead compound 2 (Liu et al. J Med Chem 54:5747–5768, 2011 ), 35 new quinoxalinone derivatives were explored in this study. Outline of the structure–activity relationships (SARs) revealed that compound BH6870 ( 36 ) showed high anti-HCV potency ( EC_50 = 0.21 M ) and a good cell safety index (SI = 47.19 ). SARs analysis indicated that quinoxalin-2(1 H )-one containing a 4-aryl-substituted thiazol-2-amine moiety was optimal for antiviral activity. Introducing a hydrogen-bond acceptor (such as ester or amide group) at the C-3 position of quinoxalin-2(1 H )-one was beneficial for the antiviral potency, and especially, N , N -disubstituted amide was far superior to N -monosubstituted amide. Incorporation of more than one halogen (fluorine or chlorine atom) or a strong electron-withdrawing group on the benzene ring of the thiazole-phenyl moiety might reduce electron atmosphere density further and resulted in a dramatical loss of activity. The NH-group of the lactam moiety was clearly required for anti-HCV activity. Graphical Abstract Design and synthesis of quinoxalin-2(1 H )-one derivatives as new non-nucleoside small-molecule HCV inhibitors. BH6870 ( 36 ), showing higher antiviral potency and a good cell safety index, was identified.

S-aryltriazole Acyclonucleosides: Synthesis and Biological Evaluation Against Hepatitis C Virus.

Synthesis of Janus Type Nucleoside Analogues and Their Preliminary Bioactivity

Discovery of 5-Alkyl-2-pyrazol-oxazolidin-4-one Derivatives As Novel Hepatitis B Virus Capsid Assembly Modulators

Structure–activity relationship studies on quinoxalin-2(1 H )-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870

Structure-activity Relationships of Cryptopleurine Analogs with E-ring Modifications As Anti-Hepatitis C Virus Agents.

Design, Synthesis, Molecular Modeling Studies and Biological Evaluation of N'-Arylidene-6-(benzyloxy)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide Derivatives as Novel Anti-HCV Agents

New 3-[(4-hydroxy-6-methly-2(1h)-pyridinones)-3-yl]-4-substituted-(1h)1,2,4- Triazole-5-Thiones: Efficient Synthesis, X-Ray Crystallographic Analysis, and Antitumor Activity

Synthesis and biological evaluation of novel pentacyclic triterpene α-cyclodextrin conjugates as HCV entry inhibitors

Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability

Design and synthesis of imidazo[1,2-α][1,8]naphthyridine derivatives as anti-HCV agents via direct C-H arylation.

Novel Aryltriazole Acyclic C-azanucleosides As Anticancer Candidates

Synthesis and Anti-Hiv Activity of Triazolo-fused 3′,4′-Cyclic and 4′-Spiro Nucleoside Analogues

Design, synthesis, and biological evaluation of novel (E)-1-arylethan-1-one O-((3-arylisoxazol-5-yl) methyl) oxime derivatives as potent non-nucleoside HBV inhibitors

Synthesis of 1,2,3- Triazole Nucleoside Analogues

Design, Synthesis, and Biological Evaluation of γ-Aminopropyl Silatrane-Acyclovir Hybrids with Immunomodulatory Effects.

Exploring azomethine ylides reactivity with acrolein through cycloaddition reaction and computational antiviral activity assessment against hepatitis C virus

Synthesis, Characterization, and Biological Evaluation of Some Novel Quinoxaline Derivatives as Antiviral Agents

Study on 2-arylthio-5-iodo pyrimidine derivatives as novel nonnucleoside inhibitors against hepatitis B virus DNA replication.

5-Iodo-2-arylalkylthio-6-aryl pyrimidin-4(3H)-ones as non-nucleoside anti-HBV agents

Synthesis of Antiviral Acyclic C-nucleosides Incorporating 4-Thiazolinones Structure

Design, synthesis, and antiviral activities evaluation of novel quinazoline derivatives containing sulfonamide moiety